Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that ...

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study ...

Orforglipron (pronounced or-for-GLIP-ron) might be a mouthful to say, but Indianapolis-based Eli Lilly and Co. sees this ...

These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing ...

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

Weight-loss medications continue to grow in popularity ... findings are "promising," it was funded by Eli Lilly, the manufacturer of Zepbound. "This may raise questions about potential conflicts of ...

Experts say that semaglutide and tirzepatide can help patients with heart failure lose weight, but limited NHS access is ...